DSpace About DSpace Software 日本語

01 奈良県立医科大学 >
012 大学院 >
0122 学位請求論文 >
01221 博士論文(医学) >
2015年度 >

Please use this identifier to cite or link to this item: http://hdl.handle.net/10564/3068

Title: Cytotoxic human peripheral blood-derived γδT cells kill glioblastoma cell lines: implications for cell-based immunotherapy for patients with glioblastoma.
Other Titles: ヒト細胞傷害性γδT細胞は膠芽腫細胞株を殺傷する:膠芽腫患者に対する免疫細胞治療の意義
Authors: Nakazawa, Tsutomu
Nakamura, Mitsutoshi
Park, Young Soo
Motoyama, Yasushi
Hironaka, Yasuo
Nishimura, Fumihiko
Nakagawa, Ichiro
Yamada, Shuichi
Matsuda, Ryosuke
Tamura, Kentaro
Sugimoto, Tadashi
Takeshima, Yasuhiro
Marutani, Akiko
Tsujimura, Takahiro
Ouji, Noriko
Ouji, Yukiteru
Yoshikawa, Masahide
Nakase, Hiroyuki
Keywords: γδT cell
T-cell receptor
Issue Date: Jan-2014
Publisher: Springer US
Citation: Journal of neuro-oncology Vol.116 No.1 p.31-39(2014.01)
Abstract: Glioblastoma (GBM) is a highly aggressive brain tumor for which novel therapeutic approaches, such as immunotherapy, are urgently needed. Zoledronate (ZOL), an inhibitor of osteoclastic activity, is known to stimulate peripheral blood-derived γδT cells and sensitize tumors to γδT cell-mediated killing. To investigate the feasibility of γδT cell-based immunotherapy for patients with GBM, we focused on the killing of GBM cell lines by γδT cells and the molecular mechanisms involved in these cell–cell interactions. Peripheral blood mononuclear cells were expanded in ZOL and interleukin (IL)-2 for 14 days, and γδT cells were enriched in the expanded cells by the immunomagnetic depletion of αβT cells. Gliomas are resistant to NK cells but susceptible to lymphokine-activated killer cells and some cytotoxic T lymphocytes. When the γδT cell-mediated killing of three GBM cell lines (U87MG, U138MG and A172 cells) and an NK-sensitive leukemia cell line (K562 cells) were tested, 32 % U87MG, 15 % U138MG, 1 % A172, and 50 % K562 cells were killed at an effector:target ratio of 5:1. The γδT cell-mediated killing of all three GBM cell lines was significantly enhanced by ZOL and this ZOL-enhanced killing was blocked by an anti-T cell receptor (TcR) antibody. These results indicated that TcR γδ is crucial for the recognition of ZOL-treated GBM cells by γδT cells. Since the low level killing of GBM cells by the γδT cells was enhanced by ZOL, γδT cell-targeting therapy in combination with ZOL treatment could be effective for patients with GBM.
Description: 博士(医学)・甲第635号・平成27年5月28日
© Springer Verlag. The definitive version is available at " http://dx.doi.org/10.1007/s11060-013-1258-4 "
URI: http://hdl.handle.net/10564/3068
ISSN: 0167594X
Academic Degrees and number: 24601A635
Degree-granting date: 2015-05-28
Degree name: 博士(医学)
Degree-granting institutions: 奈良県立医科大学
Appears in Collections:2015年度

Files in This Item:

File Description SizeFormat
01_甲635本文の要旨.pdf甲635本文の要旨209.9 kBAdobe PDFView/Open
02_甲635審査要旨.pdf甲635審査要旨1.03 MBAdobe PDFView/Open
03_甲635本文.pdf甲635本文4.07 MBAdobe PDFView/Open

Items in DSpace are protected by copyright, with all rights reserved, unless otherwise indicated.


Valid XHTML 1.0! DSpace Software Copyright © 2002-2010  Duraspace - Feedback